The complex and aggressive nature of sepsis makes it particularly challenging to manage, and mortality among sepsis patients remains unacceptably high. Second only to heart attack, it is the leading cause of death in the intensive care unit. As many as 750,000 patients progress into severe sepsis each year in U.S. hospitals, and approximately 200,000 of these patients do not survive.1
The need for more effective strategies to help manage sepsis is urgent. Procalcitonin (PCT) is a critical piece of the puzzle, yet the biomarker is underutilized in the United States.
We offer a series of educational webinars led by US experts in Procalcitonin (PCT) focusing on the role of PCT in the diagnosis and management of sepsis.
1. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.